Neurofit (Drug Discovery) Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Employees
-
46
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Neurofit (Drug Discovery) General Information
Description
Operator of a preclinical contract research organization intended to evaluate treatments for central and peripheral nervous system disorders in the biopharmaceutical industry. The company provides validated in vivo and in vitro disease models as well as experimental design support and scientific expertise to accelerate drug development programs.
Contact Information
Website
www.neurofit.com(Operating Subsidiary)
Corporate Office
- 850 Boulevard South Brant - Bioparc 1
- 67400 Illkirch-Graffenstaden
- France
Corporate Office
- 850 Boulevard South Brant - Bioparc 1
- 67400 Illkirch-Graffenstaden
- France
Neurofit (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neurofit (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neurofit (Drug Discovery) Patents
Neurofit (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| DE-60307049-D1 | Use of piperazine phenothiazine derivatives for the manufacture of a medicament having neuroprotective and / or neurotropic effects on the cns and / or pns | Inactive | 25-Apr-2003 | ||
| DE-60307049-T2 | Use of piperazine phenothiazine derivatives for the manufacture of a medicament having neuroprotective and / or neurotropic effects on the cns and / or pns | Inactive | 25-Apr-2003 | ||
| EP-1470818-A1 | Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns | Active | 25-Apr-2003 | ||
| EP-1470818-B1 | Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns | Inactive | 25-Apr-2003 | ||
| ES-2272911-T3 | Use of piperazine phenotiazine derivatives in the manufacture of a medicinal product with neuroprotector and / or neurotrophic effects on cns and / or pns. | Inactive | 25-Apr-2003 | A61K31/5415 |
Neurofit (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neurofit (Drug Discovery) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Neurofit (Drug Discovery) FAQs
-
When was Neurofit (Drug Discovery) founded?
Neurofit (Drug Discovery) was founded in 1996.
-
Where is Neurofit (Drug Discovery) headquartered?
Neurofit (Drug Discovery) is headquartered in Illkirch-Graffenstaden, France.
-
What is the size of Neurofit (Drug Discovery)?
Neurofit (Drug Discovery) has 46 total employees.
-
What industry is Neurofit (Drug Discovery) in?
Neurofit (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Neurofit (Drug Discovery) a private or public company?
Neurofit (Drug Discovery) is a Private company.
-
What is Neurofit (Drug Discovery)’s current revenue?
The current revenue for Neurofit (Drug Discovery) is .
-
Who are Neurofit (Drug Discovery)’s investors?
Neuphoria Therapeutics has invested in Neurofit (Drug Discovery).
-
When was Neurofit (Drug Discovery) acquired?
Neurofit (Drug Discovery) was acquired on 03-Mar-2020.
-
Who acquired Neurofit (Drug Discovery)?
Neurofit (Drug Discovery) was acquired by Kainova Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
